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ApoptosisMalignant mesothelioma is a highly aggressive tumor arising from serosal surfaces of the pleura and is
triggered by past exposure to asbestos. Currently, there is no widely accepted treatment for mesothelioma.
Development of effective drug treatments for human cancers requires identiﬁcation of therapeutic molecular
targets. We therefore conducted a large-scale functional screening of mesothelioma cells using a genome-
wide small interfering RNA library. We determined that knockdown of 39 genes suppressed mesothelioma
cell proliferation. At least seven of the 39 genes—COPA, COPB2, EIF3D, POLR2A, PSMA6, RBM8A, and RPL18A—
would be involved in anti-apoptotic function. In particular, the COPA protein was highly expressed in some
mesothelioma cell lines but not in a pleural mesothelial cell line. COPA knockdown induced apoptosis and
suppressed tumor growth in a mesothelioma mouse model. Therefore, COPA may have the potential of a
therapeutic target and a new diagnostic marker of mesothelioma.ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Malignant mesothelioma is a highly aggressive tumor arising from
the serosal surfaces of the pleura, peritoneum, and pericardium [1,2].
About 75% of all cases involve the pleura, and the remaining involve
the peritoneum or pericardium. Mesothelioma is associated with
previous asbestos exposure with a latency of 30–40 years. The three
main categories of mesothelioma are epithelioid (50–70% of all cases),
sarcomatoid (7–20%), and mixed/biphasic (20–30%). This tumor was
once rare, but the incidence is expected to increase worldwide over
the next several decades as a result of widespread asbestos exposure,
both occupational and environmental, in many countries [2–4].
Current treatments include some form of surgery, which may be
combined with chemotherapy and/or radiation. However, the
prognosis of patients with this multimodality therapy remains poor,
with typical post-diagnosis survival being 8–18 months [1,2]. Sig-
niﬁcantly, traditional chemotherapy has yielded poor response rates
(typically b15–20%) [1,2]. Thus, the lack of a highly effective thera-
peutic regimen for mesothelioma underscores the importance of
ﬁnding new and more effective treatments.
To develop effective drugs for treatment of human cancer, it is
important to identify therapeutic target molecules. Small interfering
RNAs (siRNA) have beenwidely used inmammalian cells to deﬁne thefunctional roles of individual genes, particularly in disease. In
addition, the development of whole-genome siRNA libraries and use
of high throughput loss-of-function screens have allowed systematic
detection of genes required for disease processes such as cancer [5–7].
We previously established a high-throughput screening procedure
[8,9] and performed a large-scale screening to identify radiation-
susceptible genes [9]. In the present study, we screened potential drug
target molecules in mesothelioma cells using the high-throughput
screening assay with a genome-wide siRNA library, containing small
double-stranded RNAs targeted to more than 8,500 human genes, and
conducted in vitro and in vivo functional analysis of several genes
identiﬁed by this screening.
Results
Primary screening
The siRNA library used in this study contained 8,589 siRNAs
consisting of nine sub-libraries: ion binding, ion channel, kinase,
membrane transporter, nucleic acid binding, phosphatase, receptor,
transcription factor, and transporter (Table 1) in a 96-well format. We
performed primary screening by transfecting each siRNA individually
into human malignant mesothelioma cells 211H [10] and measured
the remaining viable cells at four days after transfection as
determined by a sulforhodamine B-based cell proliferation assay
[8,9]. Following gene-speciﬁc siRNA transfection, we identiﬁed 383
genes for which b50% viable cells remained compared with mock-
Table 1
Summary of genes in the siRNA library and results of the ﬁrst screen using MSTO-211H
mesothelioma cell line.





Ion binding 1,479 5 23
Ion channel 349 0 2
Kinase 800 5 24
Membrane Transporter 695 0 12
Nucleic acid binding 1,951 39 117
Phosphatase 599 0 3
Receptor 1,425 16 69
Transcription factor 995 7 36
Transporter 296 6 19
Total 8,589 78 305
a % viable cells compared with mock transfected cells.
211H. Sudo et al. / Genomics 95 (2010) 210–216transfected cells (Table 1 and Supplementary Table 1). Of the 383
genes, 78 showed viability of b20%. These 78most-effective genes had
the following functional distribution: ion binding (5), kinase (5),
nucleic acid binding (39), receptor (16), transcription factor (7), and
transporter (6) (Table 1 and Supplementary Table 1).
Secondary screening
We synthesized additional siRNAs against the 78 genes identiﬁed
in the primary screening and built an original sub-library containing
156 siRNAs (two distinct siRNAs for each gene) against these 78 genes
in the 96-well format. Knockdown of each gene was achieved by each
of two distinct gene-speciﬁc siRNAs, andwemeasured viable cells at 2,
4, and 6 days after transfection. For 39 genes, COPA, COPB2, EIF3D,
POLR2A, PSMA6, RBM8A, RPL18A, OR52l1, RPA1, EIF3C,WEE1, RPL8, RPL3,
RPL19, EIF3A, RPS2, RPL6, SF3B1, KISS1R, EIF3I, LSM2, RPL4, RPL21,
POLR2F, RPL27A, RPL7, SF3B4, RPL5, RPS18, RPLP1, RPL18, KPNB1, EIF3E,
SF3B14, RPL11, EIF3G, RPL35A, RPS17, and SNRNP200, both siRNAs
reduced cell viability comparedwith the negative control (Figs. 1A and
B, and Supplementary Fig. 1). For 20 other genes, TBRG1, DIS3, OR2T27,
RPS19, SETD1A, RFX3, PHF5A, EPS8L3, MAX, ASCL2, LCE3A, ZC3H8,
C9orf98, WWOX, ITPKA, FCGR3B, NDUFAF2, SCAND3, CAT, and RXRG,
only one siRNA reduced cell viability (Supplementary Fig. 1).
Apoptosis assay of mesothelioma cells transfected with siRNAs against
seven genes
Based on the greatest negative impact on cell viability of siRNA-
mediated knockdown of genes in our screen and their functional
categories, we selected seven representative genes, COPA, COPB2,
EIF3D, POLR2A, PSMA6, RBM8A, and RPL18A, for further analysis of their
contribution to apoptosis. On treatment with speciﬁc siRNAs, the
expression of these seven genes was reduced to b10% compared with
the negative control, as assessed by real-time RT-PCR (Fig. 1C). We
ﬁrst stained nuclei of knockdown cells with Hoechst 33342 at 48 h
after transfection and observed them under the ﬂuorescence
microscope. Apoptosis in cell populations transfected with gene-
speciﬁc siRNAs targeting the seven selected genes apparently
increased compared with cells transfected with the negative control
siRNA (data not shown). Using ﬂow cytometry, we then measured
annexin V-positive apoptotic cells at 8, 24, and 48 h after transfection
(Fig. 2). In the negative control, the apoptotic population was
not increased at any time point after transfection. At 24 h after
transfection, cells transfected with siRNAs targeting ﬁve genes, EIF3D,
POLR2A, PSMA6, RBM8A, and RPL18A, contained signiﬁcantly more
apoptotic cells compared with the negative control (Pb0.01, Fig. 2B),
whereas cells transfected with COPA and COPB2 siRNAs did not. At
48 h after transfection, the apoptotic population in all seven of the
gene-knockdown cells was signiﬁcantly increased compared with thenegative control (Pb0.01; Figs. 2A and B). Among cells transfected
with the negative control or gene-speciﬁc siRNAs, the necrotic
population of cells (negative for annexin V and positive for 7-AAD)
was not increased at any time point (data not shown).
Functional analysis of COPA in mesothelioma cells
Among these 7 genes, because the COPA mRNA has been
previously reported to be highly expressed in mesothelioma
compared with normal tissues (tumor/normal ratio was 2.19) by
microarray experiments [12], we focused on further functional
analysis of COPA. To determine whether COPA protein is expressed
in mesothelioma, we conducted immunoblotting analysis in four
mesothelioma cell lines, 211H, H226, H2052, and H2452, and the
pleural mesothelial cell line, MeT-5A. COPA protein was highly
expressed in 211H, H2052, and H2452 cells, but not in H226 and
MeT-5A cells (Fig. 3A). We examined the ability of COPA siRNAs to
downregulate COPA mRNA in mesothelioma and the pleural
mesothelial cell lines by real-time RT-PCR. At 24 h after siRNA-
transfection, both siRNAs reduced COPA mRNA to b10% in 211H
cells compared with the negative control siRNA (Fig. 1C). In H2052
and Met-5A cells, COPA mRNAs were reduced to b40% compared
with control (Fig. 3B). In H226 and H2452 cells, COPA siRNAs were
insufﬁcient to reduce COPA mRNAs compared with negative control
(N60%; Fig. 3B). We then performed cell proliferation assay of COPA
siRNA-transfected 211H, H2052, and MeT-5A. Both siRNAs (COPAsi1
and COPAsi2) reduced cell viability signiﬁcantly to b10% (5.4 and
4.6%) and b35% (19.2 and 31.7%) in 211H and H2052, respectively,
compared with the negative control, whereas COPA siRNA-trans-
fected MeT-5A cells survived N60% (67.1 and 61.2%) compared with
control (Fig. 3C).
COPA siRNA treatment in a mesothelioma mouse model
To examine whether COPA siRNAs suppress tumor growth in a
mesothelioma mouse model, we ﬁrst conducted treatment experi-
ments with the pretreatment protocol in which 211H cells
transfected with COPA or negative control siRNAs were subcutane-
ously injected into nude mice. Fig. 4A shows that negative control
siRNA-transfected cells formed tumors that grew linearly with time,
whereas 211H cells transfected with both COPA siRNAs formed
tumors with signiﬁcant reductions in tumor growth compared with
the negative control (Pb0.01). Second, we conducted a local
injection protocol in nude mice bearing 211H xenografts. The
untreated 211H cells were subcutaneously inoculated into nude
mice, and COPA or negative control siRNAs were injected around
xenografts twice. The treatment of both COPA siRNAs caused
signiﬁcant inhibition in tumor growth compared with the negative
control siRNA (Pb0.05; Fig. 4B).
Immunohistochemical staining of 211H xenografted tumors was
performed two days after second injection of siRNAs to evaluate
apoptosis. We observed amarked increase of apoptotic cells in tumors
treated with both COPA siRNAs compared with the negative control
(Fig. 4C). From quantitative analysis of immunohistochemical stain-
ing, both COPA siRNAs caused 12- and 10-fold increases of TUNEL-
positive cells, respectively, compared with the negative control siRNA
(Pb0.01; Fig. 4D).
Discussion
We report here for the ﬁrst time a large-scale loss-of-function
screening to identify potential drug target molecules for mesotheli-
oma treatments. We conducted a large-scale functional screening of a
mesothelioma cell line, 211H, using a genome-wide siRNA library to
identify potential drug target molecules. Of siRNAs to 383 genes that
reduced mesothelioma cell viability by at least 50%, siRNAs to 78
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Fig. 2. Apoptotic analysis of 211H cells transfected with seven individual siRNAs against COPA, COPB2, ELF3D, POLR2A, PSMA6, RBM8A, and RPL18A and stained with annexin V and
7-amino-actinomycin D (7-AAD, DNA staining) at 8, 24, and 48 h after transfection. Living (annexin V negative and 7-AAD negative), necrotic (annexin V negative and 7-AAD
positive), and apoptotic (annexin V positive) cells were determined by a Guava PCA system. (A) Representative ﬂow cytometry dot plots at 48 h after transfection. (B) Mean
percentage values of apoptotic cell from three independent experiments, as analyzed by ANOVA with the Student–Newman–Keuls method multiple comparison test (vs. negative
control, **Pb0.01). Data are presented as means±SD from three independent experiments. Open circles represent cells transfected with negative control siRNA, closed squares
represent gene-speciﬁc siRNA (si1) of each gene, and closed triangles represent gene-speciﬁc siRNA (si2) of each gene.
Fig. 1. Cell viability and gene expression analysis of 211H transfected with seven genes, COPA, COPB2, EIF3D, POLR2A, PSMA6, RBM8A, and RPL18A. (A) Cell viability of 211H cells
transfected with 14 siRNAs against seven genes selected by primary screening shown in Supplementary Table 1 and the negative control siRNA. Cell viability about more 71 genes
were shown in Supplementary Fig. 1. Cell viability was measured by sulforhodamine B-based cell proliferation assay at 2, 4, and 6 days after transfection. Data represent mean±SD
from three independent experiments. Open circles represent cells transfected with negative control siRNA, closed squares represent gene-speciﬁc siRNA (si1) for each gene, and
closed triangles represent gene-speciﬁc siRNA (si2) for each gene. (B) Representative sulforhodamine B-stained cells at 2, 4, and 6 days after transfection. Cells transfected with
negative control siRNA or gene-speciﬁc siRNAs targeting seven genes. (C) Gene expression analysis of 211H cells transfected with siRNAs. The cDNAs were directly synthesized from
cells at 24 h after transfection with either negative control siRNA or gene-speciﬁc siRNAs targeting seven genes. Gene expression was determined by real-time RT-PCR with TaqMan
probes. The expression level of each target gene was normalized to that of 18S ribosomal RNA. Data represent mean and SD from three independent experiments.
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Fig. 3. COPA expression in mesothelioma cell lines and cell proliferation of COPA siRNA-
transfected cells. (A) COPA protein expressions were detected by immunoblot analysis
in mesothelioma cell lines (211H, H226, H2052, and H2452) and pleural mesothelial
cell line (MET-5A). (B) Expression of COPAmRNA was determined by real-time RT-PCR
with TaqMan probes. Data represent mean and SD from three independent
experiments. (C) Cell proliferation assay of COPA siRNA-transfected cells. Data are
presented as means and SD from three independent experiments.
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these genes regulate cell viability in mesothelioma. To further explore
this possibility, we newly synthesized and built an original sub-library
containing 156 siRNAs against the above-mentioned 78 genes and
assessed the effect of gene silencing on cell viability. Of these 78 genes,
we found 39 genes that reduced cell viability at 4 and/or 6 days after
transfection with gene-speciﬁc siRNAs, suggesting a crucial role forthese genes in mesothelioma cell viability and as potential drug
targets for treatment. We focused on further functional studies of
these 39 genes (mentioned below). For additional 22 genes, cell
viability was reduced by one but not both gene-speciﬁc siRNAs. This
result cannot conclusively establish whether the lack of signiﬁcant
reduction of viable cells resulted from insufﬁcient knockdown in
either siRNA or whether the result reﬂected an off-target effect [7,11].
To clearly identify which of these genes could be associated with cell
viability in mesothelioma will require further investigation using
additional siRNAs.
Of the 39 genes detected by this screening, almost all cells
transfected with siRNAs died at 4 and/or 6 days after transfection. To
determine whether apoptosis caused this cell death, we chose seven
representative genes, COPA, COPB2, EIF3D, POLR2A, PSMA6, RBM8A,
and RPL18A, based on the greatest negative impact on cell viability of
siRNA-mediated knockdown of genes in our screen and their
functional categories. According the apoptosis assay of knockdown
cells using microscopic and ﬂow cytometric analyses, apoptosis of cell
populations targeted with gene-speciﬁc siRNAs for each of the seven
genes was signiﬁcantly increased compared with cells with the
negative control siRNA. This suggests that these genes can be involved
in anti-apoptotic function. Interestingly, COPA, COPB2, EIF3D, and
PBM8A have not been known to be associated with apoptosis. Thus,
further investigation of these genesmay lead to the elucidation of new
molecular mechanisms of apoptosis.
The COPA mRNA has been previously reported to be highly
expressed in mesothelioma compared with normal tissues [12]. To
examine COPA protein expression in mesothelioma cells, we
performed immunoblotting analysis for four mesothelioma cell lines
(211H, H226, H2052, and H2452) and the pleural mesothelial cell line
(MeT-5A). The COPA protein is highly expressed in 211H, H2052, and
H2452 cells, but not in H226 and MeT-5A cells. This result suggests
that COPA could be a new therapeutic target for mesotheliomas that
highly express COPA. To test this possibility, we conducted cell
proliferation assay in 211H, H2052, and MeT-5A cells, in which COPA
siRNAs were sufﬁcient to reduce COPA mRNAs for the assay. COPA
siRNAs markedly reduced cell viability to b10% and b35% in 211H and
H2052 cells, respectively, compared with the negative control,
whereas MeT-5A cells survived N60%. We treated mesothelioma
mouse models using COPA siRNAs with both protocols (pretreatment
and local injection) and clearly showed that COPA siRNAs suppressed
tumor growth and induced apoptosis. The pretreatment protocol was
more effective than the local injection protocol. Because the
transfection efﬁciency of mesothelioma cells in dishes is expected to
be higher than that in mice, this result was probably due to the
transfection efﬁciency of COPA siRNAs. If we could ﬁnd a small
inhibitor molecule of COPA, it would help clarify this point and be a
potential drug compound for treatment of mesotheliomas that highly
express COPA.
COPA is one of the seven non-clathrin-coated vesicular coat
subunits that form the “coatomer,” which plays a role in membrane
transport between the endoplasmic reticulum and the Golgi appara-
tus [13,14]. COPA and COPB2 have a tryptophan-aspartic acid (WD)-
repeat motif and belong to a large conserved family of WD proteins
found in all eukaryotes and implicated in a variety of functions
ranging from signal transduction and transcriptional regulation to cell
cycle control and apoptosis [15]. This report and our present results
suggest that COPA and COPB2 could play a role not only in membrane
transport but also in apoptosis. Thus, further study of COPA and COPB2
might help elucidate themolecularmechanism of apoptosis. COPA and
COPB2 have been reported to interact with platelet-derived growth
factor β-receptor [16], which is a cell surface tyrosine kinase receptor,
binds SH2 domain containing proteins, activates cell growth signaling,
and is related to angiogenesis [17,18]. Tumor angiogenesis is a critical
step in tumor development through which tumors establish inde-
pendent nutrient and oxygen supply, consequently enhancing tumor
Fig. 4. Therapeutic efﬁcacy of COPA siRNA in vivo. (A) For the pretreatment protocol, siRNA-transfected 211H cells were injected subcutaneously into nude mice, and tumor
diameters were measured at a regular interval for up to 20 days and tumor volume was calculated. Results represent mean±SD (n=5) compared with negative control (**Pb0.01).
Open circles represent cells transfected with negative control siRNA, closed squares represent gene-speciﬁc siRNA (si1), and closed triangles represent gene-speciﬁc siRNA (si2).
(B) For the local injection protocol, 3 and 10 days after inoculation of 211H cells, 10 nmol of COPA siRNAs or negative control siRNA was mixed with atelocollagen, and 100 μl of each
mixture was injected around tumor. Tumor diameters were measured at a regular interval for up to 20 days and tumor volume was calculated. Results represent the mean±SD
(n=4 tumors) compared with negative control (*Pb0.05, **Pb0.01). Open triangles represent siRNA injection. (C) The effect of COPA siRNA on apoptosis in vivo.
Immunohistochemical analysis of 211H tumor xenografts stained with TUNEL (Magniﬁcation, 400×, Size bar, 50 μm). (D) The ratio of the apoptotic cells. Data are presented as
mean±SD compared with negative control (**Pb0.01).
215H. Sudo et al. / Genomics 95 (2010) 210–216growth. COPAwas highly expressed in somemesotheliomas according
to our results and the previous report [12]. These ﬁndings suggest that
COPA over-expression could play a role inmesothelioma development
through anti-apoptosis and/or angiogenesis. Further studies would
be important to explore the correlation between mesothelioma
development and potential roles of COPA in anti-apoptosis and/or
angiogenesis.
In conclusion, we conducted a large-scale functional screening in
mesothelioma cells using a genome-wide siRNA library and deter-
mined that knockdown of 39 genes suppressed cell proliferation of
mesothelioma cells, at least seven of which—COPA, COPB2, EIF3D,
POLR2A, PSMA6, RBM8A, and RPL18A—are associated with an anti-
apoptotic function. Functional characterization of these genes and
their role in apoptosis pathways may provide clues to the underlying
molecular mechanisms of cell death as well as to the development of
novel therapeutic agents for mesothelioma. In particular, COPA may
hold promise for the development of new therapy for malignant
mesothelioma that highly express COPA.Materials and methods
Cell culture
We obtained humanmalignantmesothelioma cell lines, 211H [10],
H226, H2052, and H2452, and the human pleural mesothelial cell line
MeT-5A from American Type Culture Collections (Manassas, VA). Cells
were maintained in RPMI 1640 medium (Sigma, St. Louis, MO)
supplemented with 5% fetal calf serum (JRH Biosciences, Lenexa, KS).SiRNA library
We purchased a human genome-wide siRNA library (siPerfect
Library; RNAi Co., Ltd, Tokyo, Japan) containing small double-stranded
RNAs against 8,589 human genes. This library consists of nine sub-
libraries: ion binding, ion channel, kinase, membrane transporter,
nucleic acid binding, phosphatase, receptor, transcription factor, and
transporter. We also purchased a negative control siRNA and
additional gene-speciﬁc siRNAs custom-synthesized by RNAi Co., Ltd.
Cell proliferation assay
We seeded 1.5×103 cells in each well of 96-well plates and
transfected them with siRNA (5 nM) using Lipofectamine 2000
reagent (Invitrogen, Carlsbad, CA). After 4 days, we performed cell
proliferation assay using a sulforhodamine B-based Toxicology Assay
kit (Sigma) as reported previously [8,9]. We estimated the numbers of
cells based on a standard curve obtained by serial dilutions (104 to 625
cells).
Real-time quantitative reverse transcriptase-PCR
We seeded 1.5×105 cells in a 3-cm dish and transfected themwith
siRNA (5 nM). After 24 h, we synthesized ﬁrst-strand cDNAs from
knockdown cells using the FastLane Cell cDNA kit (Qiagen, Hilden,
Germany). Predesigned and preoptimized TaqMan probes to detect
genes of interest and 18S ribosomal RNA were purchased from
Applied Biosystems (Foster City, CA). Real-time reverse transcriptase-
PCR (RT-PCR) was performed in triplicate using a Premix Ex Taq
216 H. Sudo et al. / Genomics 95 (2010) 210–216reagent (Takara-Bio, Otsu, Japan) on a Mx3000 (Stratagene, La Jolla,
CA) real-time PCR instrument. Gene expression levels were nor-
malized to 18S ribosomal RNA expression in each sample.Apoptosis analysis with Hoechst 33342 staining
We seeded 1.5×105 cells in a 6-cm dish and transfected themwith
siRNAs (10 nM). After 48 h, we added Hoechst 33342 (3 μl; 1 μg/ml;
Dojindo Laboratories, Kumamoto, Japan) to the culture medium and
incubated the cells for 60 min. The culturemediumwas then removed
and replaced with fresh medium. We observed the stained cells under
a ﬂuorescence microscope (Olympus, Tokyo, Japan).Apoptosis analysis with annexin V staining
We transfected 1.5×105 cells with siRNAs (10 nM) and harvested
them for 8, 24, and 48 h. The cells were stained with annexin V and
7-amino-actinomycin D (7-AAD) using a Guava PCA Nexin kit (Guava
Technologies, Hayward, CA) as described previously [9]. We counted
2,500 events and identiﬁed living (annexin V negative, 7-AAD
negative), apoptotic (annexin V positive, 7-AAD positive and nega-
tive), and necrotic cells (annexin V negative, 7-AAD positive) by a
Guava PCA system (Guava Technologies). Data were analyzed by
ANOVA with the Student–Newman–Keuls method multiple com-
parison test.Immunoblot analysis
We lysed cells in a buffer containing 20 mM Tris-HCl (pH 7.5),
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM
sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4,
1 µg/ml leupeptin, and 0.2 M 4-(2-Aminoethyl)-benzenesulfonyl
ﬂuoride hydrochloride. We estimated the protein concentration
using the Quick Start Bradford Protein Assay kit (Bio-Rad, Hercules,
CA). Cell lysates (40 μg) were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis, transferred to polyvinylidene
diﬂuoride membranes using the iBlot Dry Blotting System (Invitro-
gen), and probed with anti-COPA polyclonal (Abcam, Cambridge, UK)
or anti-β-actin monoclonal (Sigma) antibodies. We detected the
primary antibodies using horseradish peroxidase-linked goat anti-
mouse or anti-rabbit IgG (GE Healthcare, Little Chalfont, UK) and
visualized them by the ECL Plus kit (GE Healthcare).COPA siRNA treatment in mesothelioma mouse models
We obtained female nude mice (BALB/c-nu/nu, 5–6 weeks old)
from CLEA Japan (Tokyo, Japan) and maintained them under speciﬁc
pathogen-free conditions. For a pretreatment protocol, we transfected
211H cells (2×106) with COPA-speciﬁc (si1 or si2) or control siRNAs,
and 24 h later we implanted the cells subcutaneously into the nude
mice under ether anesthesia. The size of subcutaneous tumor was
measured twice a week using a caliper. Tumor volume was calculated
using the following formula: tumor volume (mm3)=(W×H×D)/2,
whereW is width, H is height, and D is depth inmillimeters. For a local
injection protocol, we implanted 2×106 of 211H cells subcutaneously
into nude mice under ether anesthesia. We treated the tumor-bearing
nude mice with 10 nmol of COPA-speciﬁc (si1 or si2) or control
siRNAs mixed at a ratio of 1:1 in atelocollagen (Koken, Tokyo, Japan)
by local injections at 3 and 10 days after subcutaneous tumors had
grown to approximately 20 mm3. We measured the tumor size and
calculated the tumor volume. Animal experiments were reviewed and
approved by the Institutional Animal Care and Use Committee of our
institute.TUNEL staining of xenografted tumors after treatment
We excised the tumors two days after the last siRNA treatment,
ﬁxed them in 10% neutral buffer formalin, and embedded them in
parafﬁn for sectioning and detection of apoptosis. We detected
apoptosis by terminal deoxynucleotidyl transferase-mediated deox-
yuridine triphosphate biotin nick-end labeling (TUNEL) staining using
the ApopTag Plus Peroxidase In Situ Apoptosis Detection kit
(Chemicon International, Temecula, CA), according to the manufac-
turer's protocol. Brieﬂy, we stripped nuclear proteins from DNA by
incubation in proteinase K for 15 min at room temperature, blocked
endogenous peroxidase with 0.3% H2O2 for 15 min, and incubated for
10 s with equilibration buffer. The sections were incubated in
terminal deoxynucleotidyl transferase enzyme for 1 h at 37 °C. The
reaction was terminated by incubation with stop buffer at room
temperature. The sections were incubated with anti-digoxigenin
conjugate for 30 min, and the reaction was developedwith incubation
in peroxidase substrate for 5 min. We quantiﬁed the TUNEL-stained
cells in at least four randomly selected ﬁelds at 400× magniﬁcation.
Acknowledgments
We thank Sumitaka Hasegawa for technical advices and help, and
YurikoOgawa for technical assistances. Thisworkwas supported in part
by a grant from the Ministry of Education, Culture, Sports, Science and
Technology of Japan Grant-in Aid for Young Scientists (B) 20790582.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi: 10.1016/j.ygeno.2010.02.002.
References
[1] A. Tsiouris, R.K. Walesby, Malignant pleural mesothelioma: current concepts in
treatment, Nat. Clin. Pract. Oncol. 4 (2007) 344–352.
[2] B.W. Robinson, R.A. Lake, Advances in malignant mesothelioma, N. Engl. J. Med.
353 (2005) 1591–1603.
[3] N. Kanazawa, A. Ioka, H. Tsukuma, W. Ajiki, A. Oshima, Incidence and survival of
mesothelioma in Osaka, Japan, Jpn. J. Clin. Oncol. 36 (2006) 254–257.
[4] J. Peto, A. Decarli, C. La Vecchia, F. Levi, E. Negri, The European mesothelioma
epidemic, Br. J. Cancer 79 (1999) 666–672.
[5] K. Berns, et al., A large-scale RNAi screen in human cells identiﬁes new com-
ponents of the p53 pathway, Nature 428 (2004) 431–437.
[6] J.P. MacKeigan, L.O. Murphy, J. Blenis, Sensitized RNAi screen of human kinases
and phosphatases identiﬁes new regulators of apoptosis and chemoresistance,
Nat. Cell. Biol. 7 (2005) 591–600.
[7] C.J. Echeverri, N. Perrimon, High-throughput RNAi screening in cultured cells: a
user's guide, Nat. Rev. Genet. 7 (2006) 373–384.
[8] A.B. Tsuji, et al., A fast, simple method for screening radiation susceptibility genes
by RNA interference, Biochem. Biophys. Res. Commun. 333 (2005) 1370–1377.
[9] H. Sudo, et al., A loss of function screen identiﬁes nine new radiation susceptibility
genes, Biochem. Biophys. Res. Commun. 364 (2007) 695–701.
[10] G. Bepler, et al., Characterization of the state of differentiation of six newly
established human non-small-cell lung cancer cell lines, Differentiation 37 (1988)
158–171.
[11] A.L. Jackson, et al., Expression proﬁling reveals off-target gene regulation by RNAi,
Nat. Biotechnol. 21 (2003) 635–637.
[12] G.J. Gordon, et al., Identiﬁcation of novel candidate oncogenes and tumor
suppressors in malignant pleural mesothelioma using large-scale transcriptional
proﬁling, Am. J. Pathol. 166 (2005) 1827–1840.
[13] L. Orcl, D.J. Palmer, M. Amherdt, J.E. Rothman, Coated vesicle assembly in the Golgi
requires only coatomer and ARF proteins from the cytosol, Nature 364 (1993)
732–734.
[14] J.F. Presley, et al., Dissection of COPI and Arf1 dynamics in vivo and role in Golgi
membrane transport, Nature 417 (2002) 187–193.
[15] D. Li, R. Roberts, WD-repeat proteins: structure characteristics, biological function,
and their involvement in human diseases, Cell. Mol. Life Sci. 58 (2001)
2085–2097.
[16] K. Hansen, L. Ronnstrand, C. Rorsman, U. Hellman, C.H. Heldin, Association of
coatomer proteins with the beta-receptor for platelet-derived growth factor,
Biochem. Biophys. Res. Commun. 235 (1997) 455–460.
[17] J.F. Rual, et al., Towards a proteome-scale map of the human protein-protein
interaction network, Nature 437 (2005) 1173–1178.
[18] D. Anderson, et al., Binding of SH2 domains of phospholipase C gamma 1, GAP, and
Src to activated growth factor receptors, Science 250 (1990) 979–982.
